Human papillomavirus (HPV) genotyping using paired exfoliated cervicovaginal cells and paraffin-embedded tissues to highlight difficulties in attributing HPV types to specific lesions

Journal of Clinical Microbiology

Volumn 45, Issue 10, 2007, Pages 3245-3250

  Gravitt, Patti E ^a   Van Doorn, Leen Jan ^b   Quint, Wim ^b   Schiffman, Mark ^c   Hildesheim, Allan ^c   Glass, Andrew G ^d   Rush, Brenda B ^d   Hellman, Jared ^e   Sherman, Mark E ^c   Burk, Robert D ^f   Wang, Sophia S ^c  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b DDL DIAGNOSTIC LABORATORY   (Netherlands)

^c NATIONAL CANCER INSTITUTE   (United States)

^d KAISER PERMANENTE   (United States)

^e INFORMATION MANAGEMENT SERVICES INC   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; FORMALDEHYDE; PARAFFIN;

ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DOT HYBRIDIZATION; FEMALE; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; IN SITU HYBRIDIZATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; WART VIRUS;

CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; FEMALE; GENOTYPE; HUMANS; PAPILLOMAVIRIDAE; PARAFFIN EMBEDDING; UTERINE CERVICAL NEOPLASMS; VAGINA; VAGINAL SMEARS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 35348873250     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00216-07     Document Type: Article

References (18)

1. Alvarez, R., M. Conner, H. Weiss, P. Klug, S. Niwas, U. Manne, et al. 2003. The efficacy of 9-cis-retinoic acid (aliretinoin) as a chemopreventive agent for cervical dysplasia: results of a randomized double-blind clinical trial. Cancer Epidemiol. Biomarkers Prev. 12:114-119.
2. Bauer, H. M., C. E. Greer, and M. M. Manos. 1992. Determination of genital human papillomavirus infection by consensus PCR amplification, p. 131-152. In C. S. Herrington and J. O. D. McGee (ed.), Diagnostic molecular pathology: a practical approach, vol. II. Oxford University Press, Oxford, United Kingdom.
3. Castle, P. E., M. Schiffman, P. E. Gravitt, H. Kendall, S. Fishman, H. Dong, et al. 2002. Comparisons of HPV DNA detection by MY09/11 PCR methods. J. Med. Virol. 68:417-423.
4. Goldberg, G. L., S. H. Vermund, M. H. Schiffman, D. B. Ritter, C. Spitzer, and R. D. Burk. 1989. Comparison of cytobrush and cervicovaginal lavage sampling methods for the detection of genital human papillomavirus. Am. J. Obstet. Gynecol. 161:1669-1672.
5. Gravitt, P. E., and R. Viscidi. 2004. Measurement of exposure, p. 81-100. In T. Rohan and K. V. Shah (ed.), Cervical cancer from etiology to prevention. Kluwer Academic Publishers, Dordrecht, The Netherlands.
6. Gravitt, P. E., C. L. Peyton, T. Q. Alessi, C. M. Wheeler, F. Coutlee, A. Hildesheim, et al. 2000. Improved amplification of genital human papillomaviruses. J. Clin. Microbiol. 38:357-361.
7. Harper, D. M., E. L. Franco, C. M. Wheeler, A. B. Moscicki, B. Romanowski, C. M. Roteli-Martins, et al. 2006. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367:1247-1255.
8. Jeronimo, J., and M. Schiffman. 2006. Colposcopy at a crossroads. Am. J. Obstet. Gynecol. 195:349-353.
9. Kleter, B., L. J. van Doorn, L. Schrauwen, A. Molijn, S. Sastrowijoto, J. ter Schegget, et al. 1999. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J. Clin. Microbiol. 37:2508-2517.
10. Kleter, B., L. J. van Doorn, J. ter Schegget, L. Schrauwen, K. van Krimpen, M. Burger, et al. 1998. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am. J. Pathol. 153:1731-1739.
11. Liaw, K. L., A. G. Glass, M. M. Manos, C. E. Greer, D. R. Scott, M. Sherman, et al. 1999. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J. Natl. Cancer Inst. 91:954-960.
12. Munoz, N., F. Bosch, S. de Sanjose, R. Herrero, X. Castellsague, K. Shah, et al. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348:518-527.
13. Quint, W. G., G. Scholte, L. J. van Doorn, B. Kleter, P. H. Smits, and J. Lindeman. 2001. Comparative analysis of human papillomavirus infections in cervical scrapes and biopsy specimens by general SPF(10) PCR and HPV genotyping. J. Pathol. 194:51-58.
14. Sherman, M. E., A. T. Lorincz, D. R. Scott, S. Wacholder, P. E. Castle, A. G. Glass, et al. 2003. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J. Natl. Cancer Inst. 95: 46-52.
15. Sherman, M. E., M. Schiffman, and J. T. Cox. 2002. Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS). J. Natl. Cancer Inst. 94:102-107.
16. Trimble, C. L., S. Piantadosi, P. Gravitt, B. Ronnett, E. Pizer, A. Elko, et al. 2005. Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin. Cancer Res. 11:4717-4723.
17. van Doorn, L. J., W. Quint, B. Kleter, A. Molijn, B. Colau, M. T. Martin, et al. 2002. Genotyping of human papillomavirus in liquid cytology cervical specimens by the PGMY line blot assay and the SPF(10) line probe assay. J. Clin. Microbiol. 40:979-983.
18. Yuan, C. C., W. Miley, and D. Waters. 2001. A quantification of human cells using an ERV-3 real time PCR assay. J. Virol. Methods 91:109-117.